Gelonghui, March 26, 丨 Xingkerong Pharmaceutical (06833.HK) announced that in its annual results for the year ended December 31, 2023, the Group's revenue increased 11.8% to RMB 2.54 billion. Among them, sales revenue of human albumin injections increased by about RMB 250 million, mainly due to the increase in sales volume. During the reporting period, net profit attributable to company owners was RMB 42.4 million; basic and apportioned profit per share was RMB 0.02 (2022: basic and diluted earnings per share of RMB 0.03). The Board resolved to declare a final dividend of HK0.39 cents per common share for the year ended 31 December 2023 (2022: final dividend of HK0.98 cents for the year ended 31 December 2022).
The Group is committed to continuously optimizing and expanding the company's marketing network, which has become a key component of the company's development strategy. The Group has built a strong and refined internal sales team, and the Group also maintains close cooperation with many professional third-party promotion service providers.
Facing rapid changes in the market, the Group focuses on building a marketing team that can respond quickly to market changes and efficiently execute strategies with “flexibility” and “professionalism and efficiency” as the core principles. The group has comprehensively optimized the team structure, and attached importance to the discovery and cultivation of talents to ensure that team members can continue to improve and adapt to future market needs. At the same time, the company has further improved the team's performance management system to ensure that each product line receives proper attention and investment through scientific and rational allocation of sales resources, and enhances the team's overall business operation efficiency.
The Group will continue to adhere to the core values of innovation and development, continuously explore and expand new business areas, strengthen internal management, improve risk control capabilities, and ensure the sustainable and healthy development of the enterprise. The company is firmly committed to creating value for shareholders, providing a good career development platform for employees, and actively fulfilling corporate social responsibility.